Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014, Article ID 391256, 8 pages
http://dx.doi.org/10.1155/2014/391256
Case Report

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer

1Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco
2Université Mohammed V-Souissi, Rabat 8007, Morocco

Received 3 June 2014; Revised 23 September 2014; Accepted 25 September 2014; Published 21 October 2014

Academic Editor: Sercan Aksoy

Copyright © 2014 Narimane Salmi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Hinchey, C. Chaves, B. Appignani et al., “A reversible posterior leukoencephalopathy syndrome,” The New England Journal of Medicine, vol. 334, no. 8, pp. 494–500, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. K. J. Ahn, W. J. You, S. L. Jeong et al., “Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping,” Neuroradiology, vol. 46, no. 12, pp. 978–983, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Provenzale, J. R. Petrella, L. C. Cruz, J. C. Wong, S. Engelter, and D. P. Barboriak, “Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome,” The American Journal of Neuroradiology, vol. 22, no. 8, pp. 1455–1461, 2001. View at Google Scholar · View at Scopus
  4. D. J. Covarrubias, P. H. Luetmer, and N. G. Campeau, “Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images,” American Journal of Neuroradiology, vol. 23, no. 6, pp. 1038–1048, 2002. View at Google Scholar · View at Scopus
  5. D. M. Robertson, H. B. Dinsdale, T. Ayashi, and J. Tu, “Cerebral lesions in adrenal regeneration hypertension,” American Journal of Pathology, vol. 59, no. 1, pp. 115–132, 1970. View at Google Scholar · View at Scopus
  6. H. B. Dinsdale, D. M. Robertson, and R. A. Haas, “Cerebral blood flow in acute hypertension,” Archives of Neurology, vol. 31, no. 2, pp. 80–87, 1974. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. M. Gijtenbeek, M. J. Van Den Bent, and C. J. Vecht, “Cyclosporine neurotoxicity: a review,” Journal of Neurology, vol. 246, no. 5, pp. 339–346, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. V. L. Stott, M. A. Hurrell, and T. J. Anderson, “Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed,” Internal Medicine Journal, vol. 35, no. 2, pp. 83–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. R. K. Garg, “Posterior leukoencephalopathy syndrome,” Postgraduate Medical Journal, vol. 77, no. 903, pp. 24–28, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. H. A. G. Teive, I. V. Brandi, C. H. F. Camargo et al., “Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation,” Arquivos de Neuro-Psiquiatria, vol. 59, no. 3, pp. 784–789, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Bakshi, V. E. Bates, L. L. Mechtler, P. R. Kinkel, and W. R. Kinkel, “Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings,” Epilepsia, vol. 39, no. 3, pp. 295–299, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Belaramani, V. Lai, C. H. Li, A. C. W. Lee, and N. S. Kwong, “Reversible posterior leukoencephalopathy syndrome in Chinese children induced by chemotherapy: a review of five cases,” Hong Kong Medical Journal, vol. 17, no. 1, pp. 61–66, 2011. View at Google Scholar · View at Scopus
  13. V. Skiba, M. Etienne, and J. A. Miller, “Development of chronic epilepsy after recurrent episodes of posterior reversible encephalopathy syndromeassociated with periodic lateralized epileptiform discharges,” Seizure, vol. 20, no. 1, pp. 93–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Kwon, J. Koo, and S. Lee, “Clinical spectrum of reversible posterior leukoencephalopathy syndrome,” Pediatric Neurology, vol. 24, no. 5, pp. 361–364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Ay, F. S. Buonanno, P. W. Schaefer et al., “Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI,” Neurology, vol. 51, no. 5, pp. 1369–1376, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. R. B. Schwartz, S. M. Bravo, R. A. Klufas et al., “Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases,” American Journal of Roentgenology, vol. 165, no. 3, pp. 627–631, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. R. C. S. Seet and A. A. Rabinstein, “Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment,” QJM, vol. 105, no. 1, pp. 69–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Sawaya, W. Radwan, and S. Hammoud, “Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer,” Medical Oncology, vol. 31, no. 2, article 831, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Dersch, O. Stich, K. Goller et al., “Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin,” Journal of Neurology, vol. 260, no. 5, pp. 1406–1407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Lazarus, S. Amundson, and R. Belani, “An association between bevacizumab and recurrent posterior reversible encephalopathy syndrome in a patient presenting with deep vein thrombosis: a case report and review of the literature,” Case Reports in Oncological Medicine, vol. 2012, Article ID 819546, 4 pages, 2012. View at Publisher · View at Google Scholar
  21. P. C. P. Lau and B. Paunipagar, “Posterior reversible encephalopathy syndrome with bevacizumab,” Hong Kong Medical Journal, vol. 17, no. 1, pp. 80–81, 2011. View at Google Scholar · View at Scopus
  22. C. F. Levy, K. Z. Oo, F. Fireman et al., “Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab,” Pediatric Blood & Cancer, vol. 52, no. 5, pp. 669–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Bürki, K. Badie, P. Bartoli, P. Bernard, J. L. Montastruc, and H. Bagheri, “Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen,” British Journal of Clinical Pharmacology, vol. 65, no. 5, pp. 793–794, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. G. El Maalouf, E. Mitry, A. Lacout, A. Lièvre, and P. Rougier, “Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab,” Journal of Neurology, vol. 255, no. 2, pp. 295–296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Koopman, E. W. Muller, and C. J. A. Punt, “Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case,” Diseases of the Colon & Rectum, vol. 51, no. 9, pp. 1425–1426, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Peter, N. Hausmann, A. Schuster, and H. F. Boehm, “Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab,” Clinical and Experimental Ophthalmology, vol. 36, no. 1, pp. 94–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Ozcan, S. J. Wong, and P. Hari, “Reversible posterior leukoencephalopathy syndrome and bevacizumab,” The New England Journal of Medicine, vol. 354, no. 9, pp. 981–982, 2006. View at Google Scholar · View at Scopus
  28. J. A. Allen, A. Adlakha, and P. R. Bergethon, “Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer,” Archives of Neurology, vol. 63, no. 10, pp. 1475–1478, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Glusker, L. Recht, and B. Lane, “Reversible posterior leukoencephalopathy syndrome and bevacizumab,” The New England Journal of Medicine, vol. 354, no. 9, pp. 980–981, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Matsunaga, K. Miwa, K. Araki et al., “A case of reversible posterior leukoencephalopathy syndrome (RPLS) induced by modified FOLFOX6,” Gan To Kagaku Ryoho, vol. 39, no. 8, pp. 1283–1286, 2012. View at Google Scholar · View at Scopus
  31. Y. Nagata, Y. Omuro, T. Shimoyama et al., “A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime),” Gan to kagaku ryoho. Cancer & chemotherapy, vol. 36, no. 7, pp. 1163–1166, 2009. View at Google Scholar · View at Scopus
  32. U. Sharief and D. J. Perry, “Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin,” Clinical Colorectal Cancer, vol. 8, no. 3, pp. 163–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. D. M. Pinedo, F. Shah-Khan, and P. C. Shah, “Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5320–5321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. R. Skelton, R. M. Goldberg, and B. H. O'Neil, “A case of oxaliplatin-related posterior reversible encephalopathy syndrome,” Clinical Colorectal Cancer, vol. 6, no. 5, pp. 386–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. N. A. Pirzada, I. I. Ali, and R. M. Dafer, “Fluorouracil-induced neurotoxicity,” Annals of Pharmacotherapy, vol. 34, no. 1, pp. 35–38, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. C. H. Takimoto, Z. H. Lu, R. Zhang et al., “Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency,” Clinical Cancer Research, vol. 2, no. 3, pp. 477–481, 1996. View at Google Scholar · View at Scopus
  37. A. Toyokawa, T. Nakajima, K. Inui et al., “A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer,” Gan To Kagaku Ryoho, vol. 36, no. 7, pp. 1167–1169, 2009. View at Google Scholar · View at Scopus
  38. F. Teraishi, T. Suzuki, M. Nakamoto et al., “A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6,” Gan to Kagaku Ryoho, vol. 36, no. 5, pp. 867–869, 2009. View at Google Scholar · View at Scopus
  39. R. Han, Y. M. Yang, J. Dietrich, A. Luebke, M. Mayer-Pröschel, and M. Noble, “Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system,” Journal of Biology, vol. 7, no. 4, article 12, 2008. View at Publisher · View at Google Scholar · View at Scopus